Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a landmark decision that will further restrict multinational drug companies from introducing their internationally marketed brands in India, the Delhi High Court rejected German drug maker Bayer's plea to stop the Drug Controller General of India - the Indian drug regulator - from granting marketing approval to generic drug maker Cipla for kidney/liver cancer drug Nexavar (sorafenib)
You may also be interested in...
Merck And Cipla Bury Differences To Co-market Raltegravir In India
Merck agreed to co-market its patented HIV product raltegravir in India with rival Cipla, bringing to end what had started as an attempt for a voluntary license and could have veered toward a compulsory license.
Bayer Suffers Nexavar Setback As India's Supreme Court Dismisses Linkage of Patent With Generic Marketing Approval
MUMBAI - German pharma and healthcare firm Bayer suffered yet another jolt in its two-year attempt to establish a patent linkage to registration of generic versions of its kidney and liver cancer drug Nexavar (sorafenib) as India's Supreme Court dismissed the company's pleas and referred the case back to the Delhi High Court
Bayer Suffers Nexavar Setback As India's Supreme Court Dismisses Linkage of Patent With Generic Marketing Approval
MUMBAI - German pharma and healthcare firm Bayer suffered yet another jolt in its two-year attempt to establish a patent linkage to registration of generic versions of its kidney and liver cancer drug Nexavar (sorafenib) as India's Supreme Court dismissed the company's pleas and referred the case back to the Delhi High Court